Cumberland Pharma reported FY 2025 net revenues of USD 44.5 million, up 18%, including USD 10.5 million from Kristalose, USD 11.9 million from Sancuso, USD 9.5 million from Vibativ, USD 4.7 million from Caldolor and USD 3.3 million from Talicia. In Q4 2025, net revenues were USD 13.7 million, up 31%. FY 2025 net loss was USD 2.9 million, while adjusted earnings were USD 1.7 million and cash flow from operations was USD 4.9 million. Cumberland Pharma ended 2025 with USD 76.8 million in total assets, USD 52.3 million in liabilities, and USD 24.9 million in shareholders’ equity, including USD 11.4 million in cash and cash equivalents and USD 5.2 million on its credit facility. During 2025, Cumberland Pharma expanded internationally with Vibativ approvals and launches including China and Saudi Arabia, and received regulatory approval in Mexico for its ibuprofen injection via a partnership with PiSA. The company added Talicia to its commercial portfolio through a co-commercialization agreement with RedHill Biopharma, under which Cumberland Pharma records U.S. Talicia sales and equally shares net revenues. The company also said Caldolor received a permanent CMS J-code (J1741) in December 2025, establishing a reimbursable pathway, and reported positive top-line Phase II FIGHT DMD results for ifetroban in Duchenne muscular dystrophy-related heart disease, with the FDA providing Fast Track designation in early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL00744) on March 03, 2026, and is solely responsible for the information contained therein.